Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156442 | 1.00 | SLC6A5 (0.38) | SLC6A5PRKCAMMP12SMN1; SMN2PRMT5 | |
| SCHEMBL4151555 | 0.94 | PRKCA (0.39) | SLC6A5PRKCAMMP12EGFR | |
| SCHEMBL4151551 | 0.94 | PRKCA (0.39) | SLC6A5PRKCAMMP12EGFR | |
| SCHEMBL4151954 | 0.94 | PRMT5 (0.33) | SLC6A5PRKCAMMP12PRMT5WDR77 | |
| SCHEMBL4151957 | 0.94 | PRMT5 (0.33) | SLC6A5PRKCAMMP12PRMT5WDR77 | |
| SCHEMBL4139614 | 0.92 | PRMT5 (0.36) | SLC6A5PRKCAMMP12PRMT5WDR77 | |
| SCHEMBL4139612 | 0.92 | PRMT5 (0.36) | SLC6A5PRKCAMMP12PRMT5WDR77 | |
| SCHEMBL4144455 | 0.92 | PRMT5 (0.35) | SLC6A5PRMT5WDR77EGFRNPC1 | |
| SCHEMBL4144460 | 0.92 | PRMT5 (0.35) | SLC6A5PRMT5WDR77EGFRNPC1 | |
| SCHEMBL4146072 | 0.90 | PRKCA (0.38) | SLC6A5PRKCAMMP12GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | SLC6A5 2329/4885PRKCA 4320/4885MMP12 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.